Full-Time

VP – Early Clinical Research Physician

Confirmed live in the last 24 hours

Schrödinger

Schrödinger

501-1,000 employees

Computational platform for biopharmaceutical research

Enterprise Software
Biotechnology
Healthcare

Compensation Overview

$260k - $325kAnnually

Senior

Cambridge, MA, USA + 1 more

More locations: New York, NY, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • M.D./Ph.D. or a MD with a focus on oncology (preferably board-certified in medical oncology or hematology/oncology) with significant scientific research experience
  • Minimum of 5 years of experience in early-phase clinical development of oncology drugs, including experience leading clinical research within the pharmaceutical industry or academia is preferred
  • Strong knowledge of clinical trial design and statistical analysis
  • Experience interacting with regulatory agencies (FDA, EMA)
  • Excellent communication skills, both written and verbal
  • Ability to work collaboratively in a fast-paced, dynamic environment
Responsibilities
  • Provide medical leadership in the design and conduct early clinical Phase 1 and Proof-of-Concept development trials, assess clinical safety and efficacy data, and write clinical study reports, clinical sections of INDs, Investigator Brochures
  • Work closely with biomarker, drug safety, clinical operations translational research scientists. You will interpret reports, prepare oral and written results of product research, and participate in the discussion and prioritization of strategies formulated within the oncology and immunology disease areas
  • Work collaboratively with the cross-functional compound development team on strategic planning, study design and execution of early-phase clinical trials, including protocol development, safety monitoring, and data analysis.
  • Collaborate with translational sciences to validate potential biomarkers for patient selection and pharmacodynamic evaluation
  • Lead outreach and interactions with key opinion leaders, clinical investigators, and other key stakeholders to build relationships and ensure alignment on clinical development plans and clinical study execution
  • Provide medical oversight for clinical trials and ensure patient safety and ensure clinical trials are conducted in accordance with all relevant regulations and guidelines, including Good Clinical Practice (GCP)
  • Contribute to clinical sections of regulatory submissions and represent Schrodinger at regulatory meetings
  • Participate in the review of preclinical data and support decision-making related to drug development
  • Stay current with emerging scientific and clinical developments in oncology and translational medicine

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by utilizing sophisticated algorithms and simulations to predict molecular behavior, which assists researchers in identifying potential drug candidates more efficiently. What sets Schrödinger apart from its competitors is its extensive global reach, serving clients in over 70 countries, and its dual focus on both software licensing and collaborative drug discovery programs. The company's goal is to advance scientific research and innovation by enhancing its computational platform and fostering partnerships that lead to successful drug development.

Company Stage

Grant

Total Funding

$362.7M

Headquarters

New York City, New York

Founded

1990

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Schrödinger's rapid identification of development candidates, such as SGR-1505, significantly accelerates the drug discovery process, offering a competitive advantage.
  • Recent investments from firms like Duality Advisers LP and Moody Aldrich Partners LLC indicate strong market confidence in Schrödinger's growth potential.
  • The company's expansion into new space in New York reflects its growth trajectory and commitment to scaling its operations.

What critics are saying

  • The high costs associated with expanding physical space and investing in new technologies could strain financial resources if not managed carefully.
  • The competitive nature of the drug discovery and computational chemistry sectors means Schrödinger must continuously innovate to maintain its edge.

What makes Schrödinger unique

  • Schrödinger's unique integration of physics-based computational methods with machine learning sets it apart in the drug discovery landscape.
  • The company's ability to triage billions of compounds and identify development candidates in a fraction of the typical time showcases its technological edge.
  • Schrödinger's commitment to ESG initiatives, as highlighted in their annual Corporate Sustainability report, adds a layer of corporate responsibility that differentiates it from many competitors.

Help us improve and share your feedback! Did you find this helpful?